BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33554287)

  • 1. The Suggested Importance of PBRM1 Mutation in Predicting Postoperative Recurrence of Localized Clear Cell Renal Cell Carcinoma.
    Goldberg H
    Ann Surg Oncol; 2021 Apr; 28(4):1889-1891. PubMed ID: 33554287
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence.
    Chalmers ZR; Johnson A; Ali SM; Frampton GM; Miller V; Ross JS; Pal SK
    Eur Urol Focus; 2018 Mar; 4(2):267-269. PubMed ID: 28753749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status.
    Kocak B; Durmaz ES; Ates E; Ulusan MB
    AJR Am J Roentgenol; 2019 Mar; 212(3):W55-W63. PubMed ID: 30601030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
    Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
    Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
    Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma.
    Ohsugi H; Yoshida T; Ohe C; Ikeda J; Sugi M; Kinoshita H; Tsuta K; Matsuda T
    Ann Surg Oncol; 2021 Apr; 28(4):2359-2366. PubMed ID: 32940805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comments on "Relationship between body composition and PBRM1 mutations in clear cell renal cell carcinoma: a propensity score matching analysis".
    Pontes-Silva A; Kovaleva O; Gadzhiakhmedova A; Luchina A; Sinelnikov M; Maslennikov R; Musaeva A; Zharova N; Zharikova T; Zharikov Y
    Rev Assoc Med Bras (1992); 2023; 69(9):e20230721. PubMed ID: 37729382
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
    Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
    Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy.
    Feng G; Fang F; Liu C; Zhang F; Huang H; Pu C
    Int Urol Nephrol; 2012 Dec; 44(6):1663-9. PubMed ID: 22826148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment.
    Russo P
    Urology; 2011 Apr; 77(4):847-8. PubMed ID: 21477710
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma.
    Laguna MP
    J Urol; 2015 Jan; 193(1):71-2. PubMed ID: 25523651
    [No Abstract]   [Full Text] [Related]  

  • 15. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M; Fushimi A; Matsumoto K; Oya M
    Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling.
    Lane BR; Li J; Zhou M; Babineau D; Faber P; Novick AC; Williams BR
    J Urol; 2009 Feb; 181(2):849-60. PubMed ID: 19095258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does one plus one always equal two?
    Askar M; Chueh SC; Huang TE; Sankari BR
    Lancet; 2012 Mar; 379(9822):1272. PubMed ID: 22464387
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
    Liu Y; Liu H; Liu W; Zhang W; An H; Xu J
    World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.